Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Gilead’s 4Q Financial Results | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Gilead’s 4Q Financial Results

HIV portfolio drives growth with flagship Biktarvy and oncology revenues driven by cell therapy franchise and Trodelvy.

By: Anthony Vecchione

Gilead
4Q Revenues: $7.4 billion (+2%)
4Q Earnings: $1.6 billion (earnings were $376 million 4Q21)
FY Revenues: $27.3 billion (flat)
FY Earnings: $4.6 billion (-26%)
Comments: Total fourth quarter revenue of $7.4 billion up 2% primarily due to increased sales in Oncology, HIV and hepatitis C virus (HCV), partially offset by lower Veklury (remdesivir) sales. Total product sales excluding Veklury rose 9% to $6.3 billion.

Veklury sales decreased 26% to $1.0 billion for the quarter and decreased 30% to $3.9 billion for the year, primarily driven by lower rates of COVID-19 related hospitalizations.   

Biktarvy (bictegravir 50mg/emtricitabine (FTC) 200mg/tenofovir alafenamide (TAF) 25mg) sales increased 15% to $2.9 billion in the quarter reflecting higher demand and favorable pricing dynamics. Descovy (FTC 200mg/TAF 25mg) sales increased 13% to $537 million primarily driven by favorable pricing dynamics as well as higher demand, partially offset by lower channel inventory.

HIV sales increased 5% to $4.8 billion reflecting higher demand and favorable pricing dynamics, partially offset by channel inventory dynamics. HCV product sales increased 12% to $439 million, primarily driven by increased patient starts and favorable pricing dynamics in the U.S., partially offset by fewer starts in Europe. Hepatitis B virus (HBV) and hepatitis delta virus (HDV) sales decreased 4% to $255 million. Vemlidy (TAF 25 mg) sales decreased 2% primarily by lower demand and pricing dynamics outside of the U.S. Hepcludex (bulevirtide) contributed $13 million in the fourth quarter as launch activities continued across Europe.

Cell Therapy sales increased 75% to $419 million for the quarter. Yescarta (axicabtagene ciloleucel) sales increased to $337 million, primarily driven by increased demand in relapsed or refractory (R/R) large B-cell lymphoma (LBCL) in the U.S. and Europe. Tecartus (brexucabtagene autoleucel) sales increased to $82 million, driven by increased demand in adult R/R B-cell precursor acute lymphoblastic leukemia (ALL) and mantle cell lymphoma (MCL) in the U.S. and Europe.

Trodelvy (sacituzumab govitecan-hziy) sales increased 65% to $195 million for the quarter and increased 79% to $680 million for the year, reflecting continued adoption in metastatic triple-negative breast cancer (TNBC) in the U.S. and Europe.


Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters